Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14359593 | 0.78 | HCRTR1 (0.57) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL6973124 | 0.76 | GAA (0.73) | KDM4ENPC1ALDH1A1HSD17B10TSHR | |
| SCHEMBL5727790 | 0.75 | FBP1 (0.69) | KDM4ENPC1ALDH1A1HSD17B10TSHR | |
| SCHEMBL3544581 | 0.74 | KDM4E (1.00) | KDM4EALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL14359454 | 0.74 | HCRTR1 (0.64) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL3549843 | 0.74 | SCD5 (0.57) | KDM4ENPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL20827295 | 0.72 | TP53 (0.74) | KDM4ENPC1ALDH1A1TSHRCYP2C19 | |
| SCHEMBL18255042 | 0.71 | NPC1 (0.65) | KDM4ENPC1ALDH1A1HSD17B10TSHR | |
| SCHEMBL8410149 | 0.71 | ALDH1A1 (0.69) | KDM4ENPC1ALDH1A1HSD17B10TSHR | |
| SCHEMBL14359633 | 0.71 | HCRTR1 (0.52) | KDM4ENPC1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | KDM4E 702/4885NPC1 1594/4885ALDH1A1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.